Reply to “Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus”
2023; Wiley; Volume: 130; Issue: 2 Linguagem: Inglês
10.1002/cncr.35134
ISSN1097-0142
AutoresYasmin Leshem, Yardenna Dolev, Nava Siegelmann‐Danieli, Sarah Sharman Moser, Lior Apter BPharm, Gabriel Chodick, Alla Nikolaevski‐Berlin, Sivan Shamai, Ofer Merimsky, Ido Wolf,
Tópico(s)Drug Transport and Resistance Mechanisms
ResumoCancerEarly View REPLY Reply to “Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus” This article relates to: Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus Ming-Cheng Guan MD, Qian Ding MD, Jing Ning MD, Hong Zhu MD, PhD, Cancer First Published online: November 21, 2023 Yasmin Leshem MD, PhD, Yasmin Leshem MD, PhD orcid.org/0000-0002-8264-1308 Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Department of Immunology, Weizmann Institute of Science, Rehovot, IsraelSearch for more papers by this authorYardenna Dolev MD, Yardenna Dolev MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorNava Siegelmann-Danieli MD, Nava Siegelmann-Danieli MD Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorSarah Sharman Moser MSc, Sarah Sharman Moser MSc Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, IsraelSearch for more papers by this authorLior Apter BPharm MSc, Lior Apter BPharm MSc Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, IsraelSearch for more papers by this authorGabriel Chodick PhD, Gabriel Chodick PhD Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorAlla Nikolaevski-Berlin PhD, Alla Nikolaevski-Berlin PhD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorSivan Shamai MD, Sivan Shamai MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorOfer Merimsky MD, Ofer Merimsky MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorIdo Wolf MD, Ido Wolf MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this author Yasmin Leshem MD, PhD, Yasmin Leshem MD, PhD orcid.org/0000-0002-8264-1308 Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Department of Immunology, Weizmann Institute of Science, Rehovot, IsraelSearch for more papers by this authorYardenna Dolev MD, Yardenna Dolev MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorNava Siegelmann-Danieli MD, Nava Siegelmann-Danieli MD Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorSarah Sharman Moser MSc, Sarah Sharman Moser MSc Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, IsraelSearch for more papers by this authorLior Apter BPharm MSc, Lior Apter BPharm MSc Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, IsraelSearch for more papers by this authorGabriel Chodick PhD, Gabriel Chodick PhD Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorAlla Nikolaevski-Berlin PhD, Alla Nikolaevski-Berlin PhD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorSivan Shamai MD, Sivan Shamai MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorOfer Merimsky MD, Ofer Merimsky MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelSearch for more papers by this authorIdo Wolf MD, Ido Wolf MD Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this author First published: 21 November 2023 https://doi.org/10.1002/cncr.35134Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Leshem Y, Dolev Y, Siegelmann-Danieli N, et al. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer. Cancer. 2023; 129(18): 2789-2797. doi:10.1002/cncr.34918 2Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017; 69(3): 345-357. doi:10.1016/j.jacc.2016.10.060 3Andrew BY, Brookhart MA, Pearse R, Raghunathan K, Krishnamoorthy V. Propensity score methods in observational research: brief review and guide for authors. Br J Anaesth. 2023;131(5): 805-809. doi:10.1016/j.bja.2023.06.054 4Cortellini A, D’Alessio A, Cleary S, et al. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023; 29(14): 2714-2724. doi:10.1158/1078-0432.ccr-22-3116 5Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of metformin versus placebo on new primary cancers in Canadian Cancer Trials Group MA.32: a secondary analysis of a phase III randomized double-blind trial in early breast cancer. J Clin Oncol. Published online September 11, 2023. doi:10.1200/jco.23.00296 6Wen J, Yi Z, Chen Y, et al. Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials. BMC Med. 2022; 20(1):402. doi:10.1186/s12916-022-02599-4 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Referência(s)